Abstract: An apparatus that includes a body, an initiation device, an actuator, and a driver. The body has a cradle sized and configured to receive a linear surgical stapler operable to clamp and staple tissue with a plurality of staples. The actuator is in communication with the initiation device and the initiation device is coupled with the body. The driver is operatively coupled with the actuator and is configured to mechanically couple with a firing assembly of the linear surgical stapler. The initiation device is configured to be manipulated by a user to activate the actuator so that the actuator actuates the driver relative to the body, thereby driving the firing assembly distally to fire the linear surgical stapler.

Abstract: A method for the cosmetic caring of the skin and/or mucosa, comprising applying a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin, wherein the postbiotic is preferably a bacterial lysate preferably obtained from bacteria heterologously expressing the at least one bacteriocin and/or endolysin and wherein the postbiotic and the at least one bacteriocin and/or endolysin have a synergistic effect in the cosmetic caring method.

Abstract: Disclosed herein are a pharmaceutical flotation device suitable for extended release of a pharmaceutical product in a stomach of a subject, the flotation device comprising a polymeric matrix that comprises a first polymeric material, a second polymeric material, and a crosslinking agent, wherein the first polymeric material and the second polymeric material form a hydrogel network; and the crosslinking agent is configured to generate additional crosslinks in at least the first polymeric material upon exposure to an aqueous solution having a pH of from 1 to 5, and a method of forming the pharmaceutical flotation device.

Abstract: The present disclosure relates to amorphous solid dispersions comprising (6aR,9aS)-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-2-((4-(6-fluoropyridin-2-yl)phenyl)methyl)-cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2H)-one and an excipient, as well as related methods of making and using such dispersions.

Abstract: The present invention features methods for reducing alcohol intake, intake of drugs of abuse, food intake, or to increase fat breakdown or lipolysis by administering a sphingosine-1-phosphate receptor modulator.

Abstract: This invention pertains to the field of plant extraction and separation technology and provides a polysaccharide compound, GLP-4, with a defined molecular structure, effective in treating emphysema and pulmonary fibrosis, and exhibiting antitumor effects. The molecular formula is: (C162H270O135)n. The polysaccharide compound is obtained by extracting from a residue of Ganoderma lucidum processed with alkaline solution under high temperature and high pressure, followed by column chromatographic separation. The polysaccharide compound features excellent water solubility and is readily absorbed by the human body. The polysaccharide compound shows superior efficacy in treating emphysema and pulmonary fibrosis compared to pirfenidone and is also effective for patients with advanced cancer (those who are no longer surgical candidates, with a life expectancy of only three to six months, and still eligible for chemotherapy).

Abstract: The present invention provides a preparation method of pharmaceutical composition for treating chronic stroke, involving injection via brain into the cranium of a patient having chronic stroke for six months or more; the pharmaceutical composition is a suspension at least comprising adipose-derived stem cells treated by cell expansion, an active synergistic component and a growth factor, wherein the expression level of CD34 and CD45 of the adipose-derived stem cells treated by cell expansion is 10% or less, and the expression level of CD90 and CD105 is 90% or more; the active synergistic component is an extracellular vesicle; the growth factor is at least one selected from the group consisting of HGF, G-CSF, Fractalkine, IP-10, EGF, IL-1?, IL-1?, IL-4, IL-5, IL-13, IFN?, TGF? and sCD40L. The present invention overcomes the limitations of previous cell therapy and provides a cell-based preparation that is clinically safe and therapeutically effective for chronic cerebral stroke.

Abstract: The present disclosure relates to methods for treating, managing, or reducing the severity of one or more neurodegenerative disorders by administration of Candida rugosa lipase (CRL) to a patient in need thereof. The present disclosure also relates to pharmaceutical compositions comprising CRL for treating, managing, or reducing the severity of one or more neurodegenerative disorders. The present disclosure also relates to dietary supplements comprising CRL for improving memory and/or cognitive function in a subject in need thereof.

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

Abstract: The invention provides anti-SIRPA antibodies, methods of generating such antibodies, and therapeutic uses and methods employing the antibodies.

Abstract: Recombinant proteins that stimulate an immune response in the presence of naturally inhibitory ligand binding are described. The recombinant proteins include an extracellular domain of an inhibitory immune cell protein and an intracellular domain of a stimulatory immune cell protein connected via a transmembrane domain. The recombinant proteins can be used to stimulate immune cell activation in the fight against cancers and infectious diseases, among other uses.

Abstract: Procedure for obtaining an artificial corneal construct by 3D printing. The procedure comprises the following stages: i. providing a composition in the form of bioink comprising type I collagen or a mixture of type I, type V and/or type VI collagen at a concentration between 0.2 and 80 mg/ml, at a pH between 3.4 and 9 and where the composition optionally comprises proteoglycans of corneal origin selected from the group consisting of chondroitin sulfate, dermatan sulfate and keratan sulfate or any combination thereof at a concentration between 1 and 10 g/ml; ii.

Abstract: Interventional procedures on the carotid arteries are performed through a transcervical access while retrograde blood flow is established from the internal carotid artery to a venous or external location. A system for use in accessing and treating a carotid artery includes an arterial access device, a shunt fluidly connected to the arterial access device, and a flow control assembly coupled to the shunt and adapted to regulate blood flow through the shunt between at least a first blood flow state and at least a second blood flow state. The flow control assembly includes one or more components that interact with the blood flow through the shunt.

Abstract: A heart lung machine (HLM) includes a plurality of actuators and a peripheral processing unit configured to receive a set of parameter data from the plurality of actuators. The HLM includes a peripheral display device configured to present a subset of the set of parameter data. The HLM also includes a plurality of actuator control units (ACUs), where each of the plurality of ACUs is operably connected to one of the plurality of actuators; and a control assembly comprising a control display device and a plurality of input control devices, where each of the control input devices is operably connected to one of the plurality of actuators.

Abstract: Methods for applying a therapeutic agent coating to an extended-wear device and the systems created thereby are disclosed. For example, a method for coating an extended-wear device using N-TIPS provides therapeutic agent coating for localized treatment in a patient using an extended-wear device for monitoring or treatment of illness or injury, wherein such methods can be used on polymeric films or within polymeric tubes.

Abstract: The present disclosure relates to a microfluidic vaporizer, an aerosol delivery device that may include such vaporizer, and methods for forming an aerosol. A microfluidic vaporizer can comprise a substrate that defines: a reservoir configured to hold a liquid; a heater adapted to vaporize the liquid; and a capillary channel configured for movement of the liquid from the reservoir to the heater. An aerosol delivery device can comprise a shell and a microfluidic vaporizer. The microfluidic vaporizer and aerosol delivery device can be used for forming aerosols with precise and reproducible compositions.

Abstract: A liquid ventilation system includes a reservoir holding a perfluorochemical (“PFC”) fluid, and a suction pump connected to the reservoir to reduce pressure within the reservoir. A sensor is configured to measure an intra-lung pressure. An appliance is configured to be disposed within a patient. The appliance carries an injector to supply the PFC fluid through the appliance. An extraction valve is disposed on an extraction line between the appliance and the reservoir. The extraction valve is arrangeable between a first position enabling fluid communication from the appliance to the reservoir and a second position disabling fluid communication from the appliance to the reservoir.

Abstract: Disclosed is a noninvasive mechanical ventilation (NIMV) treatment using an oronasal mask with continuous positive airway pressure (CRAP) and bilevel positive airway pressure (BiPAP) that by voice and vibrationally warns the patient to inhale and exhale at an adjustable time period instead of a person giving inhale-exhale command during the treatment process (approximately 2 hours) of patients diagnosed with hypercapnic respiratory failure (PCO2 [partial carbon dioxide] level above 45 mmHg) who suffer from drowsiness with a decrease in consciousness levels, meets the above-mentioned requirements, eliminates all disadvantages and brings some additional advantages.

Abstract: Apparatuses, systems, and methods are provided for controlling one or more assemblies of an energy generation system. The method may include selecting at least a portion of the one or more assemblies, transmitting at least one control signal associated with the selected at least a portion of the one or more assemblies, receiving the control signal at a communication module of the one or more assemblies, and modifying an operational parameter of the one or more assemblies responsive to the received control signal to avoid contact between the one or more assemblies and obstacles. The operational parameter may be associated with a position of the at least a portion of the one or more assemblies relative to a ground surface. The operational parameter may additionally or alternatively be a range of angle of the at least a portion of the one or more assemblies.

Abstract: A method of controlling an agricultural harvester includes a step of receiving past sensor signals from a field sensor of a first agricultural vehicle, the past sensor signals representing a field or crop property at specified locations in an agricultural field. The method further includes a step of, while harvesting, receiving real-time sensor signals from a field sensor of the agricultural harvester, the real-time sensor signals representing the field or crop property at a current location in the agricultural field. Based on the past sensor signals and the real-time sensor signals, a field prediction is determined representing the field or crop property at a future location in the agricultural field. Based on the field prediction, an operational parameter of the agricultural harvester is controlled.